CBMG Stock UPDATES Cellular Biomedicine Group Inc. (CBMG) 20.55

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellular Biomedicine Group Inc. (CBMG) 20.55 $CBMG

Cellular Biomedicine Group to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - 2 hrs 56 mins ago
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that the Company will ring The NASDAQ Stock Market Closing Bell on Monday, August 18, 2014 at 4:00 P.M. EDT. A live webcast will be available at https://new.livestream.com/nasdaq/live.

Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology and U.S. Patent
GlobeNewswire - Mon Aug 04, 8:16AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China ("AG" and its founder's U.S. patent for a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

Cellular Biomedicine Group Announces Discontinuation of Consulting Business Segment
GlobeNewswire - Mon Jun 30, 8:05AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the discontinuation of the Company's consulting business segment. The consulting business is expected to be classified as discontinued operations, effective July 1, 2014.

Cellular Biomedicine Group Completes Enrollment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Thu Jun 26, 7:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group Announces Closing of $10 Million Private Placement Offering
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the closing of a private placement transaction under which it sold an aggregate of 1,492,537 shares (the "Shares" of the Company's common stock, par value $0.001 per share (the "Common Stock" , to selected private investors (the "Investors" at $6.70 per share, for total gross proceeds of approximately $10 Million.

Cellular Biomedicine Group Releases Positive Six-Month Data From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Thu Jun 19, 7:30AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) today released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin(TM) human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.

Cellular Biomedicine Group Commences Trading of Its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Wed Jun 18, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock commences trading on NASDAQ under the ticker symbol "CBMG" effective today, June 18, 2014.

Cellular Biomedicine Group Approved for Listing on the NASDAQ Capital Market
GlobeNewswire - Mon Jun 16, 7:00AM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "CBMG" on June 18, 2014. The Company's common stock will continue to trade as "CBMG" on the OTCQB until the market closes on June 17, 2014.

Cellular Biomedicine Group Releases Positive Results From Phase I Clinical Trial for Hepatocellular Carcinoma
GlobeNewswire - Mon Mar 24, 11:53AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy
GlobeNewswire - Mon Mar 17, 12:28PM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma.

Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.

Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.

Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair
GlobeNewswire - Fri Jan 03, 11:45AM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.

Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Fri Dec 13, 2:33PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Cellular Biomedicine Group Announces Change of Auditor
PR Newswire - Wed Sep 11, 8:28AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO" as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC" .

Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Sep 06, 6:00AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.

Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Thu Aug 22, 10:48AM CDT
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
PR Newswire - Fri Aug 16, 10:17AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a developer of proprietary cell therapies for the treatment of degenerative diseases and cancers, this week reported financial results and business highlights for the quarter and six months ended June 30, 2013.

CRWEPRESSRELEASE Daily Stock Watch Harris & Harris Group, Inc., (NASDAQ:TINY), Crown Equity Holdings Inc. (OTCQB:CRWE), and Cellular Biomedicine Group (OTCQB:CBMG)
WorldStockWire - Tue Jul 30, 11:00AM CDT
CRWEpressrelease.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:

Cellular Biomedicine Group Completes Enrollment in Phase I Clinical Trial for Knee Osteoarthritis
PR Newswire - Mon Jul 22, 9:25AM CDT
Cellular Biomedicine Group (OTCQB:CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 165

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 98

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 165

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Navitas Semiconductor Stock Soars on Strong Q4 Performance

Updated Category News Views 257

Climbing Higher: NVTS Takes Off After Solid Earnings Out of nowhere, Navitas Semiconductor is buzzing with energy, and it’s no coincidence. After posting its fourth-quarter results, the stock skyrocketed—up over 25%. A quarterly loss of 5 cents per share? No biggie—it’s right where analysts expected. But that revenue? $7.30 million, cruising past the $6.95 million...

Continue Reading
Exploring the Expanding Sodium Sulfide Market with Insights

Updated Category News Views 126

Overview of the Global Sodium Sulfide Market The global sodium sulfide market is on a promising upward trajectory, with forecasts estimating its size to reach US$ 17.47 billion by 2034. This notable growth is expected to take place at a compound annual growth rate (CAGR) of 4.8% from 2024 through 2034, as outlined in a recent research study. Sodium sulfide finds extensive...

Continue Reading
Discover the Latest Innovations in Cordless Vacuum Technology

Updated Category News Views 207

Discover Tineco's New Cordless Vacuum Models Always innovating, Tineco has unveiled two remarkable cordless vacuum cleaners designed for modern living: the PURE ONE Station 5 and PURE ONE A50S. Both models combine state-of-the-art technology with practical features, making floor cleaning a breeze. With these intelligent vacuums, cleaning becomes a more pleasant...

Continue Reading
Carisma Therapeutics Initiates Voluntary Delisting from Nasdaq

Updated Category News Views 206

Carisma Therapeutics Unveils Delisting Plans from Nasdaq Carisma Therapeutics Inc. (OTCID: CARM) recently announced that its Board of Directors has approved a pivotal decision to voluntarily delist its common stock from The Nasdaq Stock Market LLC. This strategic move is aimed at deregistering the company’s common stock to suspend and ultimately conclude its reporting...

Continue Reading
Bragg's New Pineapple Turmeric Blend: A Refreshing Wellness Choice

Updated Category News Views 358

Bragg's Exciting New Product Launch A Tropical Twist on Bragg's Iconic ACV Hits Shelves Nationwide Introducing the Pineapple Turmeric ACV Blend Bragg Live Food Products, Inc. is making waves by expanding its product variety with a delightful new blend – the Pineapple Turmeric Apple Cider Vinegar (ACV) Blend. This innovative concoction signifies a fresh approach toward...

Continue Reading